
May 31 (Reuters) - The U.S. Food and Drug Administration has approved Moderna's MRNA.O next-generation COVID-19 vaccine for all individuals aged 65 and above, the company said on Saturday, the first endorsement since the regulator tightened requirements.
The vaccine has also been approved for individuals aged 12 to 64 with at least one or more underlying risk factors, Moderna said in a statement.